{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:59:09Z","timestamp":1794844749957,"version":"4.9.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with advanced cardiac immunoglobulin light chain (AL) amyloidosis have a poor prognosis. Early hematologic and cardiac responses can prolong survival, but predictors of these outcomes have yet to be clarified. We report on 142 patients with newly diagnosed stage IIIb AL amyloidosis. After a median follow-up of 60\u00a0months, the median overall survival (OS) was 9\u00a0months. Independent baseline factors associated with shorter OS were symptom onset to diagnosis &amp;gt;6\u00a0months (hazard ratio [HR], 1.94; P\u00a0= .003); bone marrow plasmacytosis \u2265 10% (HR, 1.98; P\u00a0= .01); troponin I &amp;gt; 0.635\u00a0ng\/mL (HR, 1.62; P\u00a0= .04); New York Heart Association class III or IV (HR, 1.67; P\u00a0= .04); and 6-minute walk test distance\u00a0&amp;lt; 200\u00a0m (HR, 1.85; P\u00a0= .01). Early hematologic (within 1\u00a0month) and cardiac (within 3\u00a0months) responses were significantly associated with longer survival. In a 1-month landmark analysis, patients with a hematologic very good partial response, partial response, and no response had a median OS of 47, 25, and 5\u00a0months, respectively (P\u00a0&amp;lt; .0001). Patients with cardiac response at 3\u00a0months had significantly longer OS (47 vs 11\u00a0months; P\u00a0&amp;lt; .0001). On multivariable modeling, bortezomib use was associated with early hematologic and cardiac responses and longer OS. Symptom onset to diagnosis duration of &amp;gt;6\u00a0months and difference between the involved and uninvolved free light chain &amp;gt; 350\u00a0mg\/L were independently associated with lower odds of an early cardiac response. This study identified factors predictive of treatment outcomes and survival in advanced cardiac AL amyloidosis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010324","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T13:54:38Z","timestamp":1692107678000},"page":"6080-6091","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-7669","authenticated-orcid":false,"given":"Joshua N.","family":"Gustine","sequence":"first","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-4873","authenticated-orcid":false,"given":"Andrew","family":"Staron","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"2Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-6009","authenticated-orcid":false,"given":"Lisa","family":"Mendelson","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"2Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-6271","authenticated-orcid":false,"given":"Tracy","family":"Joshi","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"2Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-9360","authenticated-orcid":false,"given":"Deepa M.","family":"Gopal","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"3Section of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-1623","authenticated-orcid":false,"given":"Omar K.","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"3Section of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-4413","authenticated-orcid":false,"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"3Section of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"},{"name":"2Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"issue":"1","key":"2023102313213335900_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2023102313213335900_bib2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"9","key":"2023102313213335900_bib3","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2023102313213335900_bib4","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023102313213335900_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023102313213335900_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2023102313213335900_bib7","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2023102313213335900_bib8","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"2023102313213335900_bib9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood.2022016348","article-title":"Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival","volume":"140","author":"Basset","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023102313213335900_bib10","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41375-021-01297-z","article-title":"Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design","volume":"35","author":"Vaxman","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2023102313213335900_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2021-152675","article-title":"Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients","volume":"138","author":"Palladini","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023102313213335900_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023102313213335900_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2020.1798224","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"issue":"4","key":"2023102313213335900_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","article-title":"A\u00a0validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis","volume":"10","author":"Sidana","year":"2020","journal-title":"Blood Cancer J"},{"issue":"36","key":"2023102313213335900_bib15","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023102313213335900_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"issue":"5","key":"2023102313213335900_bib17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2023102313213335900_bib18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023102313213335900_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2005-08-3253","article-title":"Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis","volume":"107","author":"Gillmore","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2023102313213335900_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.healun.2008.05.016","article-title":"Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy","volume":"27","author":"Lacy","year":"2008","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"8","key":"2023102313213335900_bib21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/TP.0b013e3181f10edb","article-title":"Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure","volume":"90","author":"Dey","year":"2010","journal-title":"Transplantation"},{"issue":"1","key":"2023102313213335900_bib22","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"23","key":"2023102313213335900_bib23","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A\u00a0Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"issue":"34","key":"2023102313213335900_bib24","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023102313213335900_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.14586","article-title":"The six-minute walk test in patients with AL amyloidosis: a single centre case series","volume":"177","author":"Pulido","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"2023102313213335900_bib26","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/heartjnl-2021-320703","article-title":"Prognostic importance of the 6\u00a0min walk test in light chain (AL) amyloidosis","volume":"108","author":"Cohen","year":"2022","journal-title":"Heart"},{"issue":"4","key":"2023102313213335900_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/ejh.13472","article-title":"Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis","volume":"105","author":"Schulman","year":"2020","journal-title":"Eur J Haematol"},{"issue":"6","key":"2023102313213335900_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023102313213335900_bib29","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2023102313213335900_bib30","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023102313213335900_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"28","key":"2023102313213335900_bib32","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023102313213335900_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/13506129.2019.1594759","article-title":"Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study","volume":"26","author":"Shen","year":"2019","journal-title":"Amyloid"},{"key":"2023102313213335900_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"2023102313213335900_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023102313213335900_bib37","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","article-title":"Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial","volume":"4","author":"Minnema","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"5","key":"2023102313213335900_bib38","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.18733","article-title":"First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara\u2013VCD front-line therapy","volume":"201","author":"Chakraborty","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2023102313213335900_bib39","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2021-152540","article-title":"Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network","volume":"138","author":"Kastritis","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023102313213335900_bib40","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2022-159801","article-title":"Survival benefit of birtamimab in mayo stage IV AL amyloidosis in the phase 3 VITAL Study Consistent after adjustment for key baseline variables","volume":"140","author":"Gertz","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2023102313213335900_bib41","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023102313213335900_bib42","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"45","key":"2023102313213335900_bib43","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6080\/2085204\/blooda_adv-2023-010324-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6080\/2085204\/blooda_adv-2023-010324-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:22:03Z","timestamp":1698067323000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6080\/497448\/Predictors-of-treatment-response-and-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010324","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}